Skip to main content
. 2025 Sep 1;19:e20240243. doi: 10.1590/1980-5764-DN-2024-0243

Table 1. Medicines evaluated in the present study.

Medicine Number of publications
Donepezil 7
Galantamine 5
Rivastigmine 3
Pioglitazone 2
Doxycycline 2
Rifampicin 2
Resveratrol 2
Metrifonate 2
Acetyl-L-carnitine (ALCAR) 1
Saffron 1
Tulrampator (S47445) 1
Fisostigmine 1
Cerebrolysin 1
Tacrine 1
Eptastigmine 1
Diclofenac 1
Misoprostol 1
PF-05212377 (SAM-760) 1
Scyllo-Inositol (ELND005) 1
Semagacestat 1
Huperzine A 1
Tideglusibe 1
Sodium selenate 1
Capric/Caprylic Acid Triglycerides 1
Vitamin D2 1
ABT-288 1
Simvastatin 1
Atomoxetine 1
Benfotiamine 1
Docosahexaenoic acid 1
Bexarotene 1
Hydroxychloroquine 1
Levetiracetam 1
Masupirdine 1
Rotigotine 1
Tarenflurbil 1
NeuroAiD™ (MLC601) 1
Octohydroaminoacridine 1
Velnacrine 1
EHT0202 (Etazolate hydrochloride) 1
Vitamin B 1
MK-7622 1
Edonerpic maleate (T-817MA) 1
Idalopirdine 1
UB-311 1
SB-742457 1
Omega-3 1
Tramiprosate 1
Velnacrine 1
Blarcamesine 1
Alphoscerate 1
Posiphen 1